Table 1:
Demographic and Clinical information in infants with moderate/severe WMI and mild/no WMI
| Variable | N | Overall | Mild/no WMI | Moderate/Severe WMI | P-Value |
|---|---|---|---|---|---|
| N=67 | N=48 | N=19 | |||
| Pregnancy-Induced hypertension, n (%) | 59 | 15 (25.4%) | 14 (34.1%) | 1 (5.6%) | 0.024 |
| Chronic hypertension, n (%) | 52 | 9 (17.3%) | 5 (13.9%) | 4 (25.0%) | 0.43 |
| Chorioamnionitis, n (%) | 58 | 8 (13.8%) | 6 (15.0%) | 2 (11.1%) | 0.99 |
| Antenatal Steroids, n (%) | 57 | 45 (78.9%) | 32 (82.1%) | 13 (72.2%) | 0.49 |
| Gestational Age (weeks), median, IQR | 59 | 26 (24.3, 27.5) | 26.4 (24.3, 28) | 24.8 (24.3, 26.4) | 0.28 |
| Birth Weight (grams), median, IQR | 59 | 740 (650, 990) | 740.0 (650, 1000) | 757.5 (670, 911) | 0.90 |
| Small for Gestational Age, n (%) | 59 | 20 (33.9%) | 17 (41.5%) | 3 (16.7%) | 0.06 |
| Sex (Male), n (%) | 59 | 20 (33.9%) | 13 (31.7%) | 7 (38.9%) | 0.59 |
| Ethnicity, n (%) | 0.45 | ||||
| Caucasian | 11 (18.6%) | 6 (14.6%) | 5 (27.8%) | ||
| African American | 59 | 44 (74.6%) | 31 (75.6%) | 13 (72.2%) | |
| Latino | 2 (3.4%) | 2 (4.9%) | 0 (0.00%) | ||
| Other | 2 (3.4%) | 2 (4.9%) | 0 (0.00%) | ||
| Mode of Delivery, C-section, n (%) | 41 (69.5%) | 29 (70.7%) | 12 (66.7%) | 0.76 | |
| Apgar Score <6 at 5 Minutes, n (%) | 59 | 19 (32.2%) | 12 (29.3%) | 7 (38.9%) | 0.47 |
| Out born, n (%) | 59 | 34 (57.6%) | 25 (61.0%) | 9 (50.0%) | 0.43 |
| Patent Ductus Arteriosus, n (%) | 59 | 38 (64.4%) | 26 (63.4%) | 12 (66.7%) | 0.81 |
| Patent Ductus Arteriosus, Indomethacin Treated, n (%) | 59 | 9 (15.3%) | 5 (12.2%) | 4 (22.2%) | 0.43 |
| Patent Ductus Arteriosus, Surgically Ligated, n (%) | 59 | 5 (8.5%) | 2 (4.9%) | 3 (16.7%) | 0.16 |
| Central Line Present (days), median, IQR | 58 | 49.5 (30, 93) | 49.0 (29.0, 96.0) | 50.0 (38.0, 65.0) | 0.38 |
| Positive Blood Culture Sepsis, n (%) | 59 | 19 (32.2%) | 14 (34.1%) | 5 (27.8%) | 0.63 |
| CRP on Day of NEC Onset | 51 | 3.2 (1.2, 8.2) | 4.1 (1.4, 8.2) | 1.9 (0.9, 7.4) | 0.20 |
| CRP 24h after NEC Onset | 46 | 7.8 (3, 19) | 7.7 (2.55, 19.4) | 11.1 (3.4, 18.5) | 0.57 |
| CRP 48h after NEC Onset | 37 | 9 (2.4, 21.9) | 7.4 (2.3, 20.1) | 15.6 (3.2, 22.1) | 0.28 |
| CRP at 96 Hours after NEC Onset | 42 | 6.4 (4.2, 15.1) | 5.4 (3.3, 15.1) | 7.1 (4.2, 15.6) | 0.45 |
| CRP at 1 Week after NEC Onset | 41 | 5.2 (2.5, 7.5) | 5.2 (2.2, 7.6) | 4.6 (2.5, 7.3) | 0.97 |
| CRP at 2 Week after NEC Onset | 43 | 2.6 (1.4, 5.3) | 2.6 (1.4, 5.3) | 2.8 (1.7, 5.2) | 0.73 |
| Cholestasis at NEC Onset, n (%) | 59 | 38 (64.4%) | 24 (58.5%) | 14 (77.8%) | 0.16 |
| AKI by Serum Creatinine | 0.004 | ||||
| No AKI | 27 (45.8%) | 23 (56.1%) | 4 (22.2%) | ||
| Stage 1 | 59 | 12 (20.3%) | 10 (24.4%) | 2 (11.1%) | |
| Stage 2 | 9 (15.3%) | 3 (7.3%) | 6 (33.3%) | ||
| Stage 3 | 11 (18.6%) | 5 (12.2%) | 6 (33.3%) | ||
| AKI by Urine Output | 0.45 | ||||
| No AKI | 34 (57.6%) | 22 (53.7%) | 12 (66.7%) | ||
| Stage 1 | 59 | 2 (3.4%) | 1 (2.4%) | 1 (5.6%) | |
| Stage 2 | 17 (28.8%) | 14 (34.1%) | 3 (16.7%) | ||
| Stage 3 | 6 (10.2%) | 4 (9.8%) | 2 (11.1%) | ||
| Severe AKI | 67 | 42 (62.7%) | 29 (60.4%) | 13 (68.4%) | 0.54 |
| From Birth Until NEC onset | |||||
| Dexamethasone, mg/kg, mean (± SD) | 63 | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.99 |
| Hydrocortisone, mg/kg, mean (± SD) | 67 | 1.1 (5.1) | 0.2 (1.1) | 3.4 (9.2) | 0.71 |
| From NEC onset +2 weeks | |||||
| Dexamethasone, mg/kg, mean (± SD) | 67 | 0.0 (0.1) | 0.0 (0.1) | 0.0 (0.0) | 099 |
| Hydrocortisone, mg/kg, mean (± SD) | 67 | 7.9 (11.2) | 7.7 (11.0) | 8.6 (11.9) | 0.83 |
| From end of 2 weeks to MRI | |||||
| Dexamethasone, mg/kg, mean (± SD) | 67 | 0.5 (1.7) | 0.6 (2.0) | 0.3 (0.8) | 0.99 |
| Hydrocortisone, mg/kg, mean (± SD) | 67 | 7.8 (22.6) | 6.4 (19.2) | 11.4 (29.8) | 0.88 |